AbbVie Inc.
ABBV
NYSE145.20
AbbVie Inc.
NYSE:ABBV
RECENT
PRICE
145.20
P/E
RATIO
19.36
(PEG:0.13)
P/E RATIO
RELATIVE
TO S&P
0.88
DIV
YLD
3.73%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
0.62 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 02/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
- -
- -
- -
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.00
2.93
3.20
- -
9.90
2.64
2.87
- -
11.04
2.17
3.73
- -
11.66
3.34
3.81
- -
11.84
2.60
3.64
1.61
12.54
1.11
1.85
1.67
14.20
3.20
4.35
2.05
16.10
3.74
4.12
2.33
17.72
3.33
5.92
2.58
22.15
3.85
8.65
3.77
22.49
5.33
8.64
4.30
25.95
2.62
9.51
4.37
31.78
6.53
12.44
5.24
32.66
7.55
12.38
5.57
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
- -
- -
- -
- -
- -
- -
0.20
- -
0.28
9.94
0.23
7.74
0.21
2.13
0.31
2.83
0.38
1.09
0.33
2.45
0.30
2.91
0.33
3.20
0.43
(5.71)
0.37
(5.53)
0.45
7.41
0.45
8.71
0.38
8.80
CAPEX per share
Book Value per share
- -
- -
- -
1,580
1,580
1,580
1,577
1,587
1,591
1,610
1,593
1,592
1,479
1,479
1,765
1,768
1,770
Comm.Shares outs.(m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
16.7
1.0
3.7%
49.7
2.7
3.0%
19.2
1.0
3.3%
16.1
0.7
3.9%
22.4
1.0
3.4%
25.3
1.0
3.9%
14.5
0.6
5.6%
34.4
0.9
4.9%
17.3
0.6
4.6%
19.4
0.9
3.7%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (30/9/22 | Q3)
Total liabilities
$125,298 m.
Total assets
$141,325 m.
Long-term debt
$60,399 m.
Cash and equiv.
$11,832 m.
Goodwill $31,726 m.
Retained earnings $4,953 m.
Common stock 1,771 m. shares
Market Capitalisation
$256,783 m. (as of 5/2/23)
17,444
20.8%
18,380
31.6%
18,790
30.1%
19,960
17.1%
22,859
33.0%
25,638
36.6%
28,216
34.0%
32,753
19.5%
33,266
39.0%
45,804
24.8%
56,197
31.9%
57,819
30.6%
Revenue (m)
Operating margin
1,272
3,433
1,150
5,275
897
4,128
786
1,774
836
5,144
1,189
5,953
1,501
5,309
1,765
5,687
2,017
7,882
6,471
4,616
8,521
11,542
8,289
13,407
Depreciation (m)
Net profit (m)
6.4%
19.7%
7.9%
28.7%
22.6%
22.0%
25.1%
8.9%
22.6%
22.5%
24.5%
23.2%
31.3%
18.8%
(9.4)%
17.4%
6.5%
23.7%
(36.0)%
10.1%
11.1%
20.5%
11.5%
23.3%
Income tax rate
Net profit margin
1,457
- -
12,224
8,578
14,630
3,363
10,969
14,292
4,492
4,688
10,565
1,742
5,420
29,240
3,945
6,406
36,440
4,636
4,582
30,953
5,097
(294)
35,002
(8,446)
33,934
62,975
(8,172)
(4,488)
77,554
13,076
(7,266)
64,189
15,408
(2,348)
60,399
15,994
Working capital (m)
Long-term debt (m)
Equity (m)
24.9%
18.7%
28.1%
26.5%
21.6%
156.9%
19.5%
19.3%
91.9%
13.0%
10.2%
101.8%
13.5%
13.9%
130.4%
12.0%
13.5%
128.4%
11.3%
12.5%
104.2%
17.0%
11.0%
(67.3)%
13.0%
11.5%
(96.5)%
6.5%
3.9%
35.3%
12.3%
10.5%
74.9%
13.9%
12.0%
83.8%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
39,924
8,449
9,746
Receivables
5,428
8,822
9,977
Inventory
1,813
3,310
3,128
Other
2,354
3,562
4,993
Current assets
49,519
24,173
27,928
Acc. Payable
1,452
2,276
2,882
Debt due
3,753
8,502
12,495
Other
10,380
17,883
19,817
Current liab.
15,585
28,661
35,194
100.0%
- -
100.0%
- -
38.1%
49.8%
(50.0)%
112.8%
36.0%
155.1%
37.6%
148.6%
22.6%
58.5%
1.9%
137.6%
19.2%
54.8%
(66.9)%
51.8%
19.8%
46.4%
26.5%
52.3%
Plowback ratio
Div.&Repurch. to FCF
AbbVie Inc. (US) started trading on January 3, 2013 (cik: 0001551152), operates in the Healthcare sector (Drug Manufacturers—General industry), has 50,000 full-time employees, and is led by Mr. Richard Gonzalez. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
19.51%
13.69%
Cash flow
24.48%
24.52%
Earnings
38.58%
30.05%
Dividends
22.80%
- -
Book value
-127.78%
-42.76%
Insider trading
Type
Shares
Date
Rapp Edward J
Award
239
12/31/22
Alpern Robert J
Award
46
12/31/22
Richmond Timothy J.
Exempt
42,370
12/12/22
Richmond Timothy J.
Sale
3,075
12/12/22
Richmond Timothy J.
Sale
39,295
12/12/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
8,619
10,425
12,902
13,858
45,804
2021
13,010
13,959
14,342
14,886
56,197
2022
13,538
14,583
14,812
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
1.71
(0.42)
1.31
0.02
2.62
2021
2.01
0.43
1.80
2.29
6.53
2022
2.54
0.52
2.23
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
1.00
0.99
1.19
1.19
4.37
2021
1.31
1.31
1.31
1.31
5.24
2022
1.43
1.42
1.41
- -
- -
01/31/2023
Humira Faces Competition From First U.S. Copycat
The Wall Street Journal - Read more...
07/07/2022
Senate Report Hits AbbVie’s Bermuda Tax Structure for U.S. Humira Sales
The Wall Street Journal - Read more...
04/18/2022
J&J Settles With West Virginia in Opioid Suit for $99 Million
The Wall Street Journal - Read more...
02/02/2022
Alphabet, PayPal, AMD, Meta, Starbucks: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
12/08/2021
Allergan Reaches $200 Million Opioid Settlement With New York Authorities
The Wall Street Journal - Read more...
11/02/2021
Opioid Manufacturers Score Win in California Lawsuit
The Wall Street Journal - Read more...
10/29/2021
Apple, Amazon, Lucid, Chevron: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
07/30/2021
Amazon, Pinterest, Robinhood, Chevron: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
05/18/2021
House Committee Takes On Pricing, Patents for Top-Selling Drug Humira
The Wall Street Journal - Read more...
04/30/2021
Twitter, Amazon, Clorox, Chevron: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...